No Data
Gilead Sciences : Phase 3 Data Shows 96% Reduction In HIV Infections With Lenacapavir
Express News | Barclays Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $84
Express News | Gilead Sciences Inc - Lenacapavir Shows 96% Reduction in Hiv Infections in Purpose 2 Trial
Express News | Gilead - Gilead to Begin Regulatory Filings for Lenacapavir for Prep by End of 2024
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Express News | Gilead Presents Additional Efficacy, Safety and Demographic Data From Purpose 2 Trial at 5TH Hiv Research for Prevention Conference